Recombinant Human APOA4 Protein, His-tagged
|Product Overview :
|Recombinant human APOA4 (NP_000473.2) (Met1-Ser396) was expressed with a polyhistidine tag at the C-terminus.
- Gene Information
- Related Products
|Predicted N Terminal :
|Lyophilized from sterile PBS, pH 7.4, 5% ~ 8% trehalose and mannitol.
|Molecular Mass :
|The recombinant human APOA4 consists 387 amino acids and predicts a molecular mass of 44.8 kDa.
|< 1.0 EU per μg of the protein as determined by the LAL method.
|>95 % as determined by SDS-PAGE.
|Samples are stable for up to twelve months from date of receipt at -70ºC.
|Store it under sterile conditions at -20ºC~-70ºC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 ug/ul. Centrifuge the vial at 4ºC before opening to recover the entire contents.
|Gene Name :
|APOA4 apolipoprotein A-IV [ Homo sapiens ]
|Official Symbol :
|APOA4; apolipoprotein A-IV; apo-AIV; apoA-IV; apolipoprotein A4; MGC142154; MGC142156;
|Gene ID :
|mRNA Refseq :
|Protein Refseq :
|UniProt ID :
|Chromosome Location :
|Amyloids, organism-specific biosystem; Chylomicron-mediated lipid transport, organism-specific biosystem; Disease, organism-specific biosystem; Fat digestion and absorption, organism-specific biosystem; Fat digestion and absorption, conserved biosystem; Lipid digestion, mobilization, and transport, organism-specific biosystem; Lipoprotein metabolism, organism-specific biosystem;
|◆ Recombinant Protein
|Recombinant Mouse APOA4 Protein, His (Fc)-Avi-tagged
|Recombinant Rat APOA4 Protein, His (Fc)-Avi-tagged
|Recombinant Mouse Apoa4 Protein, MYC/DDK-tagged
|Recombinant Mouse APOA4 Protein (21-395 aa), His-tagged
|Recombinant Human APOA4 Protein (21-396 aa), His-tagged
|◆ Native Protein
|Native Human Apolipoprotein AIV
|Recombinant Human APOA4 293 Cell Lysate
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (17)Ask a question
Targeting APOA4 or its related pathways may have therapeutic implications in the management of metabolic disorders and cardiovascular diseases. Researchers are exploring the potential of using APOA4-based therapies for the treatment of dyslipidemia, atherosclerosis, and obesity. However, more studies are needed to fully understand the therapeutic potential and safety of such interventions.
APOA4 has shown potential as a drug target for various metabolic conditions. Research has focused on developing therapeutics that can enhance APOA4's beneficial effects, such as increasing HDL cholesterol, improving lipid metabolism, and reducing inflammation. However, drug development targeting APOA4 is still in its early stages, and more research is required to explore its efficacy and safety.
APOA4 deficiency has been associated with impaired lipid metabolism and increased susceptibility to metabolic abnormalities. Individuals with APOA4 deficiency may have altered lipid profiles, increased levels of circulating triglycerides, decreased levels of HDL cholesterol, and potentially an increased risk of developing cardiovascular diseases and related complications.
Currently, measuring APOA4 levels is not a routine diagnostic test. However, research investigating the association between APOA4 and various diseases may provide opportunities for its use as a diagnostic marker in the future. Measurement of APOA4 levels could potentially aid in identifying individuals at higher risk for cardiovascular disease or metabolic disorders.
Yes, diet and lifestyle factors can influence APOA4 levels. Dietary fat intake, specifically monounsaturated and polyunsaturated fats, has been shown to increase APOA4 levels. Additionally, weight loss, dietary modifications, and physical activity can all have an impact on APOA4 levels, indicating that lifestyle interventions can modulate APOA4 expression.
APOA4 has multiple functions in the body. It acts as a cofactor for various enzymes involved in lipid metabolism, assists in the assembly and secretion of triglyceride-rich lipoproteins, and regulates the absorption and transportation of dietary lipids. Additionally, APOA4 has antioxidant and anti-inflammatory properties.
APOA4 has been found to play a role in the regulation of satiety and appetite. It has been proposed that APOA4 acts on specific brain regions involved in appetite control, influencing the release of neuropeptides that regulate hunger and food intake. Certain APOA4 variants have been associated with alterations in satiety signaling and increased hunger, potentially leading to overeating and obesity.
APOA4 has been implicated in various diseases and conditions. Studies have suggested that alterations in APOA4 levels or function may contribute to dyslipidemia, obesity, insulin resistance, and cardiovascular diseases. Further research is needed to fully elucidate the role of APOA4 in these conditions and to determine if it could serve as a potential therapeutic target.
While APOA4 is primarily involved in lipid transport in the bloodstream, recent research suggests its involvement in intracellular lipid transport as well. Studies have indicated that APOA4 is present in intracellular lipid droplets and may play a role in regulating lipid storage and metabolism within cells, although the exact mechanisms are still being elucidated.
Yes, genetic variations can influence APOA4 levels. Single nucleotide polymorphisms (SNPs) within the APOA4 gene have been identified and associated with variations in APOA4 levels. These genetic variations can impact APOA4 production, stability, or function, and may have implications for cardiovascular health and metabolic conditions. Studying these genetic variations can provide insights into individual differences in APOA4 biology and potential personalized treatment approaches.
Yes, genetic variations in the APOA4 gene have been reported. Certain single nucleotide polymorphisms (SNPs) in the APOA4 gene have been associated with altered lipid levels, cardiovascular disease risk, and obesity. Further research is necessary to fully understand the impact of these genetic variations on APOA4 function and disease susceptibility.
Yes, hormonal changes can influence APOA4 levels. For example, estrogen has been shown to increase APOA4 production, which may contribute to the higher levels of circulating APOA4 observed in women compared to men. Hormonal fluctuations during the menstrual cycle and menopause can impact APOA4 levels, suggesting a hormonal regulation of APOA4 expression.
APOA4 levels can be measured in the body through various laboratory tests. One common method is to measure APOA4 concentrations in the blood using techniques such as enzyme-linked immunosorbent assay (ELISA) or immunoassays. These tests can provide quantitative measurements of APOA4 levels and help assess an individual's lipid profile and cardiovascular risk. It is typically performed as part of a lipid panel or comprehensive health assessment.
Currently, there are no specific pharmacological interventions available to directly modify APOA4 levels. However, interventions that target lipid metabolism, such as drugs that lower triglyceride levels or increase high-density lipoprotein (HDL) cholesterol, may indirectly impact APOA4 levels. Future research may identify pharmacological strategies aimed specifically at modulating APOA4 expression or function.
APOA4 has a significant role in lipid metabolism. It facilitates the binding of dietary triglycerides and cholesterol to form chylomicrons, which transport these lipids from the intestines to the bloodstream. APOA4 also assists in the breakdown of triglycerides through the activation of lipoprotein lipase, an enzyme that hydrolyzes triglycerides into fatty acids and glycerol for energy utilization.
In addition to diet and physical activity, certain lifestyle factors have been associated with increased APOA4 levels. For instance, moderate alcohol consumption has been shown to elevate APOA4 levels in some studies. However, it is important to note that excessive alcohol consumption can have detrimental effects on overall health, outweighing any potential benefits on APOA4 levels.
Recent studies have suggested a potential link between APOA4 and neurological disorders such as Alzheimer's disease. In individuals carrying the APOE4 allele, which is associated with increased risk of Alzheimer's disease, APOA4 has been found to interact with amyloid-beta peptides, contributing to the formation of amyloid plaques in the brain. However, the specific role of APOA4 in the development or progression of neurological disorders is still under investigation.
Customer Reviews (5)Write a review
Considering its remarkable performance across multiple assays, I wholeheartedly endorse the usage of theAPOA4 protein in various research studies.
when employed in Western Blotting experiments, the APOA4 protein consistently generates sharp and well-defined protein bands, enabling precise visualization and analysis of protein expression.
I highly recommend the use of theAPOA4 protein in various experimental applications.
the APOA4 protein has been successfully utilized in protein electron microscopy structure analysis, providing valuable insights into molecular structures and interactions.
Considering its outstanding performance across multiple assays, I confidently endorse the inclusion of the APOA4 protein in diverse research studies.
Ask a Question for All APOA4 Products
Required fields are marked with *
My Review for All APOA4 Products
Required fields are marked with *